Stryker Q3: adj EPS $2.20 (+2.8%); organic sales +4.5%; China impairment $105M; guidance revised

STRYKER CORP

2021-Q3 EPS reported $3.48 revenue$12,407,000,000

Net sales $4.2B, +11.3% vs 2020; organic net sales +4.5% vs 2020 and +8.4% vs 2019.
Reported EPS $1.14 (down 30.1%); adjusted EPS $2.20 (up 2.8%) due to $105M impairment.
$105M impairment for China trauma/joint replacement VBP price reductions impacting Orthopaedics.
2021 outlook: organic sales growth 7%-8% from 2019; adj EPS $9.08-$9.15.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.